Sentio BioSciences
Sentio BioSciences is a US-based specialty pharmaceutical manufacturer and CDMO in Maryland Heights, Missouri, providing cGMP API and drug-product development, manufacturing, and regulatory services, alongside proprietary and generic medicines for human and animal health.
- Company typePrivate
- Founded2008
- HeadquartersMaryland Heights, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Sentio BioSciences does
Sentio BioSciences LLC is a privately held, US-based specialty pharmaceutical company and Contract Development and Manufacturing Organization (CDMO) headquartered in Maryland Heights, Missouri. Founded in 2008 by Karthik Raghavan and Flavia D'Souza, the company operates over 22,000 sq ft of cGMP-compliant infrastructure, including 9+ ISO 7/8 certified clean room suites, dedicated suites for toxic and potent compound manufacturing, on-site Water-for-Injection production, and flow/continuous manufacturing capacity scaled from 10 g to 100 kg batches with annual capacity up to 5 metric tons. It is registered with the FDA (FEI 3007640515), the DEA as a Schedule II-V Researcher (RS0683359), and the EPA as a federal large generator of hazardous waste, and has passed biennial FDA inspections in good standing since 2015.
The company operates a dual business model. On the services side, it provides CDMO offerings spanning process development, clinical and commercial cGMP manufacturing of APIs and drug products (parenterals, tablets, capsules, emulsions), analytical method development and validation, stability testing, and regulatory filing support including DMF, IND, ANDA, and NADA submissions. On the products side, Sentio markets proprietary and generic pharmaceuticals — notably Pentosan Polysulfate Sodium (the only FDA-approved injectable pentosan for equine osteoarthritis), Diroban (melarsomine dihydrochloride, the first FDA-approved generic heartworm treatment for dogs), and a pipeline of preclinical candidates (SENT008, SENT012 for human osteoarthritis) plus six generic essential medicines (SENT005-SENT011) spanning urology, oncology, cardiovascular, and other essential indications.
Revenue is generated through B2B contract manufacturing fees, sales of proprietary and generic drug products, and licensing of innovation pipelines. Customer segments are predominantly enterprise pharmaceutical and biotech companies seeking US-based cGMP manufacturing, with named partners including Apertus Pharmaceuticals and the API Innovation Center (APIIC), the latter awarding a December 2024 contract for development of two critical APIs. In June 2025, Sentio announced a $10.6 million expansion at its Maryland Heights facility creating 58 new jobs, and in July 2025 it received the SHARP Award from the Missouri Department of Labor for workplace safety excellence. The company positions itself as a contributor to US pharmaceutical supply chain resilience for essential medicines, with no disclosed revenue, funding rounds, or institutional investors in the available data.
Sentio BioSciences firmographics
Firmographics- Name
- Sentio BioSciences
- Legal name
- Sentio BioSciences LLC
- Website
- https://sentiobiosciences.com
- Company type
- Private
- Founded year
- 2008
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Sentio BioSciences is a US-based specialty pharmaceutical manufacturer and CDMO in Maryland Heights, Missouri, providing cGMP API and drug-product development, manufacturing, and regulatory services, alongside proprietary and generic medicines for human and animal health.
- Ownership category
- akta.pro rank
Sentio BioSciences industry classification
Industry- Product category
- Pharmaceutical Contract Manufacturing
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412), Scientific Research and Development Services (5417)
- SIC
- Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Small-Molecule API & Intermediates CDMO (HLAGABAA)
- akta.pro secondary industries
- Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB), Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI), Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM)
Keywords
Where Sentio BioSciences is headquartered
LocationHeadquarters
- HQ city
- Maryland Heights
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Sentio BioSciences business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain, Marketing or Sales
Revenue model
- CDMO Services: Contract Development and Manufacturing Organization services offering development through approved commercial cGMP manufacturing for APIs and drug products. Services include process development, manufacturing, analytical services, regulatory support, and stability studies.
- Essential Medicines Manufacturing: Manufacturing and commercialization of critical pharmaceuticals including generic essential medicines for human and animal health.
- Proprietary Product Licensing: Innovation and licensing of breakthrough proprietary products including Pentosan Polysulfate Sodium for equine osteoarthritis and pipeline products SENT008 and SENT012 for human osteoarthritis.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
Sentio BioSciences product offering
Product offeringCore offering
Sentio BioSciences is a US-based cGMP manufacturer operating from a 22,000+ sq ft FDA-registered facility in Maryland Heights, Missouri, providing contract development and manufacturing organization (CDMO) services for small molecule APIs and drug products from process development through commercial manufacturing. The company also develops and commercializes its own portfolio of proprietary and generic pharmaceutical products for human and animal health, including FDA-approved Pentosan Polysulfate Sodium for equine osteoarthritis, Melarsomine Dihydrochloride (Diroban) for canine heartworm disease, and pipeline candidates SENT008 and SENT012 for human osteoarthritis along with six generic essential medicines in development.
Product overview
Sentio BioSciences is a specialty pharmaceutical company offering a dual business model: (1) Proprietary and generic pharmaceutical products for human and animal health, and (2) Contract Development and Manufacturing Organization (CDMO) services. The product portfolio includes Pentosan Polysulfate Sodium (FDA-approved equine osteoarthritis treatment), two proprietary candidates in preclinical development (SENT008 and SENT012 for osteoarthritis), and six generic essential medicines (SENT005-SENT011) covering urology, oncology, cardiovascular, and medically essential indications at various development stages. CDMO services span process development, cGMP manufacturing (10kg-100kg batch scale, up to 5MT annual capacity), analytical testing, and regulatory filings. The company operates advanced manufacturing capabilities including flow chemistry, continuous manufacturing, and high-potency/toxic substance handling with containment suites.
Differentiator
Problem solved
Functional benefit
Products and services
- Pentosan Polysulfate Sodium FDA-approved injectable Pentosan Polysulfate Sodium for the treatment of osteoarthritis in horses; the only FDA-approved injectable pentosan product for this indication. Targeted at veterinary pharmaceutical companies and equine veterinary practices.
- Melarsomine Dihydrochloride (Diroban) FDA-approved generic drug (Melarsomine Dihydrochloride, brand: Diroban) for parasitic heartworm disease in dogs. The first generic drug approved for this veterinary indication. Targeted at veterinary pharmaceutical companies and canine veterinary practices.
- SENT008 Proprietary product candidate in preclinical development for the treatment of osteoarthritis in humans; available for licensing and commercialization partnerships.
- SENT012
Quantifiable outcome
- FDA inspected every 2 years since 2015 with continued compliance and good standing
- +2 more outcomes
Companies that use Sentio BioSciences
Customer profileNamed customers3 records
Segments4 records
Ideal customer profiles4 records
Sentio BioSciences technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Sentio BioSciences partnerships and signals
Strategic signalPartnerships
Eleven partnerships are on record, tiered core and minor.
- API Innovation Center (APIIC)coreAPIIC is a nonprofit working to modernize US pharmaceutical manufacturing by covering upfront capital costs for manufacturers adopting continuous production technologies. Sentio is working with APIIC on two additional active pharmaceutical ingredients, with the goal of proving that removing upfront financial barriers can enable safer and more efficient domestic production. In December 2024, APIIC awarded a contract to Sentio to advance development of two critical APIs.
- BioMap ConsortiumcoreFlavia D'Souza, Co-Founder and Head of Quality at Sentio, was elected to the BioMap Consortium Executive Steering Committee in September 2024. BioMap is a consortium focused on pharmaceutical manufacturing innovation.
- MCDC-CBRNminorConsortium member focused on medical countermeasures and chemical, biological, radiological, and nuclear defense.
- RRPVminorConsortium member focused on pharmaceutical manufacturing resilience.
- CortexminorSt. Louis-based innovation hub supporting workforce development and biotech ecosystem.
- BioSTLminorSt. Louis-based organization supporting bioscience innovation and economic development.
- Apertus PharmaceuticalscoreManufacturing partner collaborating with API Innovation Center on pharmaceutical production. Apertus operates the Missouri facility where lomustine manufacturing is being modernized.
- UMSLminorUniversity of Missouri-St. Louis - academic partnership for workforce development and research collaboration.
- Missouri S&TminorMissouri University of Science and Technology - academic partnership for workforce development and research.
- SLUminorSaint Louis University - academic partnership for research and talent development.
- Washington University in St. LouisminorWashington University - academic partnership for research collaboration and innovation.
Scale indicators8 records
Recent moves7 records
Expansion highlights5 records
Sentio BioSciences competitors and assessment
Company assessmentMarket position
Strengths4 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights8 records
Customer concentration
Sentio BioSciences social profiles
Digital presenceSentio BioSciences compliance and trust
Trust signalCompliance6 records
Sentio BioSciences financial estimates
Financial estimateRevenue estimate
Valuation estimate
Sentio BioSciences leadership team
Management profileNumber of profiles
Profiles2 records
Sentio BioSciences funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Sentio BioSciences M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Sentio BioSciences
What does Sentio BioSciences do?
Sentio BioSciences is a US-based cGMP manufacturer operating from a 22,000+ sq ft FDA-registered facility in Maryland Heights, Missouri, providing contract development and manufacturing organization (CDMO) services for small molecule APIs and drug products from process development through commercial manufacturing. The company also develops and commercializes its own portfolio of proprietary and generic pharmaceutical products for human and animal health, including FDA-approved Pentosan Polysulfate Sodium for equine osteoarthritis, Melarsomine Dihydrochloride (Diroban) for canine heartworm disease, and pipeline candidates SENT008 and SENT012 for human osteoarthritis along with six generic essential medicines in development.
Is Sentio BioSciences a public or private company?
Sentio BioSciences is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Sentio BioSciences founded?
Sentio BioSciences was founded in 2008. It employs 11 to 50 people.
Where is Sentio BioSciences based?
Sentio BioSciences is headquartered in Maryland Heights, United States, in the North America region.
How does Sentio BioSciences make money?
Three revenue lines are on record. CDMO Services are the primary driver. The others are essential Medicines Manufacturing and proprietary Product Licensing.
Does Sentio BioSciences have an API?
No public API is recorded for Sentio BioSciences.
What industry is Sentio BioSciences in?
Sentio BioSciences's product category is Pharmaceutical Contract Manufacturing. Its primary akta.pro industry code is HLAGABAA, Small-Molecule API & Intermediates CDMO, with a secondary code of HLAGABAB, Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO. Its NAICS code is 3254 and its SIC code is 2834.